MOYOM Biotech

aphranel Hosts European Doctors at 7 Chinese Clinics

Image
aphranel Hosts European Doctors at 7 Chinese Clinics

Shanghai – October 30, 2026 -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has brought European physicians to China for a week-long clinical exchange, following NMPA Class III approval for its MagiCCrystal CaHA filler in China in 2025 and EU MDR certification in 2026.

Delegation visits seven clinics across four Chinese cities

Dr. Tiago Guimarães and the aphranel® European Medical and Sales Team toured facilities with aphranel®-certified Chinese physicians. Stops included Yestar Medical Aesthetic Hospital and Huamei Zixin Medical Aesthetic Hospital in Guangzhou, and Shenzhen Fanyan Aesthetics and Shenzhen Boai Shuguang Hospital in Shenzhen. The group also visited REAL Medical Aesthetics in Shanghai, and Estee Ryan and JollyHue in Hangzhou.

The programme runs under the banner "Learning in China, Applying in Europe" and forms part of The Norns' Weave, a global academic initiative for physicians.

MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Image
MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation

The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.